Literature DB >> 9767278

Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins.

C Nakatani1, T Muramatsu, T Shirai.   

Abstract

The 180 kDa bullous pemphigoid (BP) antigen (BP180) is known to be recognized by sera from patients with BP, herpes gestationis (HG) and cicatricial pemphigoid (CP). A series of previous studies using BP180 recombinant proteins has shown that most sera from patients with BP and HG react with the NC16A domain of BP180, an extracellular non-collagenous region just adjacent to the plasma membrane. In contrast, the C-terminal region of BP180 has been reported to be one of the epitopes of CP. In the present study, we examined the immunoreactivity of 110 BP sera against the NC16A and C-terminal domains of BP180 using immunoblot analysis and enzyme-linked immunosorbent assay (ELISA). Immunoblot analysis revealed that 100 (91%) and 26 (23.5%) of the 110 BP sera recognized the NC16A and C-terminal domains, respectively. The results of the ELISA were correlated with those of immunoblotting. There were no specific or significant clinical features such as severe involvement of mucous membranes and scarring in BP patients whose sera reacted with the C-terminal region. These findings suggest that some BP sera react with the C-terminal region of BP180 without any association with the characteristic clinical features of CP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767278     DOI: 10.1046/j.1365-2133.1998.02396.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases.

Authors:  H Schumann; J Baetge; K Tasanen; F Wojnarowska; H Schäcke; D Zillikens; L Bruckner-Tuderman
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Modeling of main characteristics of bullous pemphigoid antigen-2 (BPAG2) peptide structure in serological recognition by autoantibodies.

Authors:  József Pál; Ilona Marczinovits; Ferenc Hudecz; Gábor K Tóth; Gábor Mezõ; János Molnár; Péter Németh
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

3.  Autoantibodies Against Multiple Epitopes in Bp180 and Laminin Gamma-1 in Subepidermal Blistering Skin Disease Associated with Psoriatic Erythroderma.

Authors:  Haruna Goto-Hamano; Keiko Ito; Kumiko Sakamoto-Kimura; Tadashi Terui; Bungo Ohyama; Takashi Hashimoto; Hiroyuki Hara
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

4.  Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.

Authors:  Eui Hyung Lee; Yeon Hee Kim; Sinyoung Kim; Song-Ee Kim; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

Review 5.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 6.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 7.  The significance of preclinical anti-BP180 autoantibodies.

Authors:  Yosuke Mai; Kentaro Izumi; Shoko Mai; Hideyuki Ujiie
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

8.  Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.

Authors:  Delphine Giusti; Grégory Gatouillat; Sébastien Le Jan; Julie Plée; Philippe Bernard; Frank Antonicelli; Bach-Nga Pham
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.